美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

美國抗疫概念

1,480.06

+12.920.88%

漲家數：10

跌家數：10

平家數：- -

市盈率：- -

高：1,487.39

開：1,467.14

低：1,462.61

收：1,467.14

資料載入中...

【歐股“十一羅漢”｜阿斯麥和LVMH集團收漲超2%，諾和諾德跌超2%】週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲2.39%，報714.50歐元。諾和諾德哥本哈根股價收跌2.16%，報642.80。LVMH集團漲2.35%，德國思愛普Sap漲1.03%，歐萊雅、賽諾菲、羅氏製藥漲0.81%-0.20%。阿斯利康則收跌0.42%，葛蘭素史克和雀巢至多跌2.16%，諾華製藥跌3.85%。

阿斯利康斥資併購羅沙司他在華所有權利

经济参考报

Equillium, Inc.盤中異動快速跳水5.78%

Co-Diagnostics, Inc.盤中異動大幅下挫5.04%

Ibio, Inc.盤中異動股價大漲7.20%報4.17美元

FDA官員加入輝瑞擔任高管，職業凱旋門？

褪去 “新冠概念”的“趕考人”：如何重塑競爭力？

21世纪经济报道

強生起訴三星，守住最後的顏面？

定價高達350萬美元的基因療法，上市一年未有銷售！輝瑞宣佈撤退

中国制药网

梅賽德斯-奔馳將逐步淘汰電動汽車“EQ+X”命名，以“配備 EQ 技術”取代

康方生物依沃西攜手輝瑞ADC，國際化佈局提速

Biontech Se盤中異動股價大跌5.08%報111.04美元

Vir Biotechnology, Inc.盤中異動下午盤急速下跌5.12%報8.99美元

伊諾維奧製藥盤中異動股價大跌5.45%報1.91美元

【歐股“十一羅漢”｜阿斯麥收跌2.2%，Hims減肥藥業務前景提振諾和諾德收漲約2.8%】週二，阿斯麥控股荷蘭阿姆斯特丹股價收跌2.20%，報697.80歐元。諾和諾德哥本哈根股價收漲2.78%，報657.00，美國平價減肥藥供應商Hims & Hers Health停售某些減肥藥。諾華製藥與葛蘭素史克至多漲2.35%，雀巢和阿斯利康至多漲1.41%，賽諾菲和羅氏製藥至多漲行0.7%，歐萊雅收平，德國思愛普Sap則收跌0.69%，LVMH集團跌1.14%。

製藥公司就Stelara生物仿製藥起訴三星生物公司

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1480.0557,"timestamp":1741381199999,"preClose":1467.1393,"halted":0,"volume":126573383,"delay":0,"changeRate":0.008804,"change":12.916382,"pbRate":4.037358,"amount":7265241469.443725,"amplitude":0.016884,"prevYearClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"turnoverRate":0.008184,"marketCap":1220494102080,"floatMarketCap":1198623322288,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1487.3851,"amplitude":0.016884,"preClose":1467.1393,"low":1462.6143,"pbRate":"4.037358","latestPrice":1480.0557,"volume":126573383,"delay":0,"open":1467.1393,"prevYearClose":1274.8187,"prevWeekClose":1463.5875,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"sixtyDayClose":1300.6962,"secType":"PLATE","market":"US","turnoverRate":0.008184,"peRate":31.999995,"marketCap":1220494102080,"floatMarketCap":1198623322288,"timestamp":1741381199999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514695998","title":"【歐股“十一羅漢”｜阿斯麥和LVMH集團收漲超2%，諾和諾德跌超2%】週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲2.39%，報714.50歐元。諾和諾德哥本哈根股價收跌2.16%，報642.80。LVMH集團漲2.35%，德國思愛普Sap漲1.03%，歐萊雅、賽諾菲、羅氏製藥漲0.81%-0.20%。阿斯利康則收跌0.42%，葛蘭素史克和雀巢至多跌2.16%，諾華製藥跌3.85%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514695998","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514695998?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 02:33","pubTimestamp":1740594799,"startTime":"0","endTime":"0","summary":"周三，阿斯麦控股荷兰阿姆斯特丹股价收涨2.39%，报714.50欧元。诺和诺德哥本哈根股价收跌2.16%，报642.80。LVMH集团涨2.35%，德国思爱普Sap涨1.03%，欧莱雅、赛诺菲、罗氏制药涨0.81%-0.20%。阿斯利康则收跌0.42%，葛兰素史克和雀巢至多跌2.16%，诺华制药跌3.85%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27023348414142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BJJMRZ35.SGD","LU1734074674.USD","IE00BD6J9T35.USD","LU2417539215.USD","IE00BJT1NW94.SGD","LU0823434583.USD","BK4585","BK4588","LU0211331839.USD","IE0009355771.USD","AZN","BK4212","BK4183","LU0889565916.HKD","GSK","IE0002141913.USD","IE00B2B36J28.USD","LRLCY","LU1093756168.USD","LU2063271972.USD","03165","LU0823434740.USD","LU2456880835.USD","BK4147","IE00B4R5TH58.HKD","IE00BZ1G4Q59.USD","GSK.UK","LU1829250122.USD","IE00BFTCPJ56.SGD","BK4543","BK1574","NVS","LU0154236417.USD","IE0004445239.USD","LU1093756325.SGD","LU0097036916.USD","LU2462157665.USD","NSRGY","LU0109394709.USD","NVO","BK4532","LU0320765992.SGD","01477","BK4599","BK4007","IE00BKVL7J92.USD","BK1191","BK4568","LU2236285917.USD","ASML"],"gpt_icon":0},{"id":"2514866400","title":"阿斯利康斥資併購羅沙司他在華所有權利","url":"https://stock-news.laohu8.com/highlight/detail?id=2514866400","media":"经济参考报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514866400?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 02:13","pubTimestamp":1740593625,"startTime":"0","endTime":"0","summary":"近日，阿斯利康与珐博进有限公司（简称“珐博进”）达成协议，将以约1.6亿美元（约合人民币12亿元）收购珐博进中国，拿下罗沙司他在中国的所有权利。有业内人士向《经济参考报》记者表示，作为全球医药巨头的阿斯利康并购中国公司，显示其代表行业及跨国公司持续看好中国发展机遇，也向市场传递了一个明确信号，即中国本土的生物科技和制药企业仍具备巨大的成长与投资潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502273330668420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273330668420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0889565916.HKD","AZN","LU2417539215.USD","BK4007","LU2462157665.USD","BK4568","LU1829250122.USD","BK4585","BK4588","LU0109394709.USD","LU0320765992.SGD","LU2456880835.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2514866643","title":"Equillium, Inc.盤中異動 快速跳水5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514866643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514866643?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 02:07","pubTimestamp":1740593254,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时07分，Equillium, Inc.股票出现异动，股价急速下跌5.78%。Equillium, Inc.股票所在的生物技术行业中，整体跌幅为0.39%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6400.71%、261.96%、239.71%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Pds Biotechnology Corporation，振幅分别为194.07%、49.18%、44.44%。Equillium, Inc.公司简介：Equillium Inc 是一家开发治疗自身免疫和炎症疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227020734a255286e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227020734a255286e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2514854871","title":"Co-Diagnostics, Inc.盤中異動 大幅下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854871","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514854871?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 22:53","pubTimestamp":1740581624,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时53分，Co-Diagnostics, Inc.股票出现异动，股价大幅下跌5.04%。Co-Diagnostics, Inc.股票所在的医疗器械行业中，整体涨幅为0.54%。其相关个股中，Inspira Tech Oxy Bhn Ltd C/Wts 16/07/2026 、飞天兆业、Procept Biorobotics Corporation涨幅较大，Venus Concept Inc.、Biomerica, Inc.、Sintx Technologies, Inc.较为活跃，换手率分别为11.39%、10.21%、9.87%，振幅较大的相关个股有Inogen, Inc、Rapid Micro Biosystems, Inc.、Inspira Tech Oxy Bhn Ltd C/Wts 16/07/2026 ，振幅分别为32.72%、18.09%、17.14%。Co-Diagnostics, Inc.公司简介：Co-Diagnostics Inc是一家分子诊断公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226225345abddf285&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226225345abddf285&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","BK4568","CODX"],"gpt_icon":0},{"id":"2514838859","title":"Ibio, Inc.盤中異動 股價大漲7.20%報4.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514838859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514838859?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 22:33","pubTimestamp":1740580409,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时33分，Ibio, Inc.股票出现波动，股价急速拉升7.20%。截至发稿，该股报4.17美元/股，成交量14.0798万股，换手率1.43%，振幅5.66%。Ibio, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Ibio, Inc.公司简介：iBio公司是一家临床前阶段生物技术公司，利用人工智能的力量开发精准抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223329abdded67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223329abdded67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","IBIO"],"gpt_icon":0},{"id":"2514835871","title":"FDA官員加入輝瑞擔任高管，職業凱旋門？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835871","media":"医药财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514835871?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 15:43","pubTimestamp":1740555811,"startTime":"0","endTime":"0","summary":"据悉，Patrizia Cavazzoni于今年1月离职FDA，她将领导辉瑞集团的监管、安全和医疗业务。然而，Patrizia Cavazzoni加入辉瑞担任首席医疗官的事件，可能引发多方面的讨论和影响，需从以下角度分析：1.职业旋转门的争议潜在利益冲突：Cavazzoni从监管机构转至药企，可能引发对其利用FDA内部经验或人脉的质疑。公众可能担忧监管机构与企业间的“旋转门”现象削弱监管独立性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226190634a254c14f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226190634a254c14f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999011175.SGD","LU1894683348.USD","BK4007","BK4534","LU0234572021.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4585","LU1066051498.USD","LU1894683264.USD","LU0058720904.USD","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","BK4533","BK4568","BK4581","LU1057294990.SGD","BK4550","PFE","SG9999002232.USD","SG9999001176.SGD","LU1023059063.AUD","SG9999001176.USD","LU1066053197.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4592","LU0225771236.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999002224.SGD","IE00BLSP4239.USD","BK4588","LU0122379950.USD","IE00BLSP4452.SGD","LU0170899867.USD","LU0225284248.USD","LU0306807586.USD","LU0321505868.SGD","IE0002270589.USD","BK4599","LU1883839398.USD","IE00B19Z3B42.SGD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2514100976","title":"褪去 “新冠概念”的“趕考人”：如何重塑競爭力？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514100976","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514100976?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 14:41","pubTimestamp":1740552060,"startTime":"0","endTime":"0","summary":"　　2025年开年尚不足两个月，已至少有9家生物医药领域的公司向港交所递交了IPO招股书。其中不乏迈威生物、恒瑞医药和百利天恒三家已在A股上市的药企冲刺港股。　　而作为此前“新冠概念”中的明星药企，旺山旺水和真实生物先后赴港上市也备受关注。这也是真实生物继2022年递表失效后，再次申请港股上市。　　事实上，新冠疫情期间，新冠产品的市场竞争也已近乎白热化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-02-26/doc-inemuvpf0426222.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-26/doc-inemuvpf0426222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0405327148.USD","LU1969619763.USD","02196","LU0170899867.USD","LU1064131003.USD","688062","BK4548","BK0060","BK1191","BK4551","BK1593","BK4588","LU2148510915.USD","LU0405327494.USD","BK4208","LU1064130708.USD","LU2328871848.SGD","BK0183","BK0012","BK0188","BNTX","BK4139","BK0196","ED","BK4568","BK0239","LU2346227817.USD","600276","BK4535","LU1328615791.USD","BK0028","688506","BK4585","LU2488822045.USD","BK1515"],"gpt_icon":0},{"id":"2514075905","title":"強生起訴三星，守住最後的顏面？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514075905","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514075905?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 10:53","pubTimestamp":1740538409,"startTime":"0","endTime":"0","summary":"图源：网络国外媒体称，2月24日，强生一纸诉状将三星Bioepis告上了美国新泽西州地区法院，原因是强生发现三星Bioepis与一家自有品牌供应商达成未经授权的分许可协议，强生认为这一行为严重违背了双方最初的约定。2024年7月1日，三星Bioepis宣布，乌司奴单抗的生物类似药Pyzchiva获得FDA批准，覆盖了强生原研药的所有适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226105611abdd2e7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226105611abdd2e7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1057294990.SGD","IE00B1BXHZ80.USD","LU2505996509.AUD","LU0912757837.SGD","IE00B42XCP33.USD","LU1196500208.SGD","LU1221951046.USD","BK4581","IE00B19Z3581.USD","JNJ","IE00BGHQF631.EUR","IE00B3PB1722.GBP","LU0234570918.USD","LU1162221912.USD","IE000M9KFDE8.USD","BK4568","LU0882574055.USD","BK4559","LU1023059063.AUD","LU0114720955.EUR","LU0345769128.USD","LU1280957306.USD","LU0792757196.USD","LU2129689605.HKD","IE0002270589.USD","BK4550","LU2133065610.SGD","LU0345769631.USD","BK4585","LU2602419157.SGD","BK4534","LU0795875086.SGD","LU0234572021.USD","LU2089984988.USD","LU0122379950.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4007","IE00BFTCPJ56.SGD","IE00B7SZLL34.SGD","LU0098860793.USD","LU2592432038.USD","LU0289739699.SGD","LU0889566641.SGD","LU1244550494.USD","BK4588","LU1732799900.SGD","IE0034235303.USD","LU1894683264.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2514075929","title":"定價高達350萬美元的基因療法，上市一年未有銷售！輝瑞宣佈撤退","url":"https://stock-news.laohu8.com/highlight/detail?id=2514075929","media":"中国制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514075929?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 10:40","pubTimestamp":1740537620,"startTime":"0","endTime":"0","summary":"近日，制药头部辉瑞做出一项重大决策，宣布停止 B 型血友病基因疗法 Beqvez 的研发和商业化进程。值得一提的是Beqvez 在 2024 年 4 月才刚刚获得 FDA 批准上市，定价高达 350 万美元，但是一年时间过去，辉瑞便决定终止了该药物的开发和商业化。这一系列动作表明，辉瑞正在逐步退出细胞基因疗法领域。Biomarin 公司的 A 型血友病基因疗法 RocTavian 同样销售缓慢，2023 年 6 月获 FDA 批准上市，定价 2900 万美元，2024 年销售额仅 2600 万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226110458abdd316c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226110458abdd316c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0225284248.USD","LU0456855351.SGD","LU1883839398.USD","LU0868494617.USD","LU0122379950.USD","BK4568","LU0170899867.USD","LU1066051498.USD","LU0321505439.SGD","LU1894683348.USD","SG9999002224.SGD","SG9999001176.SGD","BK4581","SG9999003800.SGD","SGXZ57979304.SGD","BK4550","IE00B19Z3581.USD","BK4585","LU0225771236.USD","PFE","LU1057294990.SGD","SG9999013999.USD","BK4534","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0985481810.HKD","IE000M9KFDE8.USD","BK4592","IE00BBT3K403.USD","LU0058720904.USD","SG9999002232.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0306807586.USD","LU0234572021.USD","LU1023059063.AUD","LU0306806265.USD","BK4588","BK4007","SG9999001176.USD","LU1066053197.SGD","LU1894683264.USD","BK4533","BK4599","IE0002270589.USD","IE00BLSP4239.USD","LU0321505868.SGD"],"gpt_icon":1},{"id":"2514539578","title":"梅賽德斯-奔馳將逐步淘汰電動汽車“EQ+X”命名，以“配備 EQ 技術”取代","url":"https://stock-news.laohu8.com/highlight/detail?id=2514539578","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514539578?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 10:26","pubTimestamp":1740536777,"startTime":"0","endTime":"0","summary":"根据外媒 Automotive News Europe 报道，梅赛德斯-奔驰正逐步淘汰电动汽车上的 EQ 前缀，未来将改用“配备 EQ 技术”后缀 ，而插电式混合动力车型则会添加“配备 EQ 混合动力技术”标签。梅赛德斯-奔驰的一位发言人表示，“我们正在强化传统的命名逻辑，未来新车型将不再使用‘EQ’。”梅赛德斯-奔驰并非唯一调整命名的欧洲豪华品牌。","market":"us","thumbnail":"https://k.sinaimg.cn/n/spider20250226/697/w959h538/20250226/cec8-2c1c922f81bf06deb8a90e9f413caf31.jpg/w120h90l50t15f2.jpg","type":0,"news_type":0,"thumbnails":["https://k.sinaimg.cn/n/spider20250226/697/w959h538/20250226/cec8-2c1c922f81bf06deb8a90e9f413caf31.jpg/w120h90l50t15f2.jpg"],"rights":{"source":"sina_tech","url":"https://tech.sina.cn/mobile/xp/2025-02-26/detail-inemukxn8238835.d.html?vt=4","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}.weibo_user{#sourceStyle#; margin-bottom: 0; display: inline-block;}.weibo_time{#sourceStyle#};","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .j_float_wbro, .j_article_wbreco","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.sina.cn/mobile/xp/2025-02-26/detail-inemukxn8238835.d.html?vt=4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_tech","symbols":["EQ","BK4139","BK4568"],"gpt_icon":0},{"id":"2514020285","title":"康方生物依沃西攜手輝瑞ADC，國際化佈局提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020285","media":"国泰君安","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514020285?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:15","pubTimestamp":1740532557,"startTime":"0","endTime":"0","summary":"2月24日，公司海外合作伙伴Summit Therapeutics宣布与辉瑞达成临床试验合作，有望深入挖掘依沃西联合辉瑞多款vedotin系列ADCs药物联合疗法在多种实体瘤中的巨大潜力。辉瑞为全球ADC领域头部玩家，有望提供丰富产品组合。多项临床布局推动下，依沃西有望在肺癌领域实现全线布局，与ADC的联合给药有望在长期进一步带来治疗模式的突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226093052a2541cfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226093052a2541cfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0122379950.USD","SG9999003800.SGD","LU0985481810.HKD","LU0170899867.USD","SG9999013999.USD","LU0306807586.USD","LU1894683264.USD","LU0306806265.USD","LU1883839398.USD","BK4585","IE0002270589.USD","BK4550","BK4080","SG9999001176.SGD","BK4588","IE00B19Z3B42.SGD","SG9999002224.SGD","LU1894683348.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU0225284248.USD","BK4534","BK4231","IE00BLSP4452.SGD","LU0321505868.SGD","LU1066053197.SGD","PFE","BK4581","SG9999011175.SGD","LU1066051498.USD","LU1023059063.AUD","LU0058720904.USD","SG9999001176.USD","LU0225771236.USD","SGXZ57979304.SGD","BK4533","BK4599","BK4007","LU0321505439.SGD","SG9999002232.USD","LU0289739699.SGD","BK4568","BK4592","ADC","LU0868494617.USD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2514204643","title":"Biontech Se盤中異動 股價大跌5.08%報111.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514204643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514204643?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 04:33","pubTimestamp":1740515604,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日04时33分，Biontech Se股票出现波动，股价大幅跳水5.08%。截至发稿，该股报111.04美元/股，成交量67.431万股，换手率0.28%，振幅6.26%。Biontech Se股票所在的生物技术行业中，整体涨幅为0.15%。Biontech Se公司简介：BioNTech是一家总部位于德国的生物技术公司，专注于开发癌症治疗药物，包括个体化免疫疗法，以及包括冠状病毒在内的传染病疫苗。冠状病毒疫苗是其首个商业化产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260433249630346b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260433249630346b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4588","BNTX","BK4551","BK4585","BK4548","BK4139","BK4568"],"gpt_icon":0},{"id":"2514043922","title":"Vir Biotechnology, Inc.盤中異動 下午盤急速下跌5.12%報8.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514043922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514043922?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 03:14","pubTimestamp":1740510894,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时14分，Vir Biotechnology, Inc.股票出现异动，股价大幅下跌5.12%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226031454a253c714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226031454a253c714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4535","VIR","BK4585","BK4139"],"gpt_icon":0},{"id":"2514048860","title":"伊諾維奧製藥盤中異動 股價大跌5.45%報1.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514048860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514048860?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 02:28","pubTimestamp":1740508126,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日02时28分，伊诺维奥制药股票出现波动，股价快速下挫5.45%。截至发稿，该股报1.91美元/股，成交量36.2775万股，换手率1.00%，振幅6.44%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。伊诺维奥制药股票所在的生物技术行业中，整体涨幅为0.09%。伊诺维奥制药公司简介：Inovio Pharmaceuticals Inc是一家总部位于美国的生物技术公司，致力于开发基于DNA的活性免疫疗法和疫苗，以治疗和预防癌症和传染病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226022846a253bdec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226022846a253bdec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4583","BK4568","INO"],"gpt_icon":0},{"id":"2514950017","title":"【歐股“十一羅漢”｜阿斯麥收跌2.2%，Hims減肥藥業務前景提振諾和諾德收漲約2.8%】 週二，阿斯麥控股荷蘭阿姆斯特丹股價收跌2.20%，報697.80歐元。諾和諾德哥本哈根股價收漲2.78%，報657.00，美國平價減肥藥供應商Hims & Hers Health停售某些減肥藥。諾華製藥與葛蘭素史克至多漲2.35%，雀巢和阿斯利康至多漲1.41%，賽諾菲和羅氏製藥至多漲行0.7%，歐萊雅收平，德國思愛普Sap則收跌0.69%，LVMH集團跌1.14%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514950017","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514950017?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 01:54","pubTimestamp":1740506070,"startTime":"0","endTime":"0","summary":"周二，阿斯麦控股荷兰阿姆斯特丹股价收跌2.20%，报697.80欧元。诺和诺德哥本哈根股价收涨2.78%，报657.00，美国平价减肥药供应商Hims & Hers Health停售某些减肥药。诺华制药与葛兰素史克至多涨2.35%，雀巢和阿斯利康至多涨1.41%，赛诺菲和罗氏制药至多涨行0.7%，欧莱雅收平，德国思爱普Sap则收跌0.69%，LVMH集团跌1.14%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26015448386051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4585","IE00B4R5TH58.HKD","IE00BKVL7J92.USD","01477","LU1093756168.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","BK4532","BK4599","LU0097036916.USD","IE00BZ1G4Q59.USD","LU1829250122.USD","LU2236285917.USD","LU2417539215.USD","LU2462157665.USD","LU2456880835.USD","AZN","IE0009355771.USD","LU0109394709.USD","BK4007","IE00BFTCPJ56.SGD","ASML","IE00BJT1NW94.SGD","GSK","GSK.UK","BK4568","LU0889565916.HKD","03165","LU0211331839.USD","LU0823434583.USD","LU0320765992.SGD","BK4578","NVS","IE00BD6J9T35.USD","IE0004445239.USD","LU0823434740.USD","BK4543","LU1734074674.USD","NSRGY","BK1574","BK4183","BK1191","IE00B2B36J28.USD","NVO","LRLCY","BK4212","LU2063271972.USD","LU0154236417.USD","BK4147"],"gpt_icon":0},{"id":"2514011579","title":"製藥公司就Stelara生物仿製藥起訴三星生物公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2514011579","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514011579?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 00:33","pubTimestamp":1740501239,"startTime":"0","endTime":"0","summary":"更新版 1-制药公司就Stelara生物仿制药起诉三星生物公司J&J 就三星与自有品牌供应商的转授权交易寻求初步禁令J&J 称转授协议将损害其市场份额三星生物于周一在美国推出生物仿制药第 5 段和第 12 段增加了诉讼细节，第 6 段试图让三星发表评论，背景贯穿全文Sneha  S K/Patrick  Wingrove. 该诉讼要求法院发布初步禁令，禁止在美国销售三星生物的Stelara生物仿制药Pyzchiva。旨在摆脱漫长专利诉讼的法律协议推迟了 Stelara 生物仿制药在美国的上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3T3PG1Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","BK4139","LU0114720955.EUR","LU1061106388.HKD","LU1732799900.SGD","IE00B2B36J28.USD","SG9999015978.USD","LU0738911758.USD","JNJ","LU1066053197.SGD","LU1093756168.USD","LU2505996681.GBP","LU1914381329.SGD","AMGN","IE00B19Z3581.USD","LU1430594728.SGD","LU0456855351.SGD","LU0889565916.HKD","BK4566","BK4588","IE0034235303.USD","LU1162221912.USD","SG9999001440.SGD","LU1023059063.AUD","LU1244550494.USD","LU0234570918.USD","LU0943347566.SGD","SG9999015945.SGD","LU1894683264.USD","LU1989772840.SGD","LU1066051498.USD","BK4568","LU0965509101.SGD","LU1244550221.USD","LU1267930813.SGD","LU2242652126.USD","LU1196500208.SGD","SG9999011175.SGD","IE00B42XCP33.USD","LU1280957306.USD","LU1989772923.USD","ABBV","BK4550","LU1291159041.SGD","IE0004445239.USD","LU0795875169.SGD","LU0868494617.USD","ALVO","LU0098860793.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":10,"pageCount":7,"totalSize":149}]}}